Robert E. Landry - Mar 21, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Mar 21, 2022
Transactions value $
-$270,821
Form type
4
Date filed
3/23/2022, 04:02 PM
Previous filing
Mar 18, 2022
Next filing
Mar 30, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale -$208K -300 -1.04% $693.00 28.7K Mar 21, 2022 Direct F1
transaction REGN Common Stock Options Exercise $153K +400 +1.4% $381.92 29.1K Mar 21, 2022 Direct
transaction REGN Common Stock Tax liability -$216K -312 -1.07% $691.31 28.7K Mar 21, 2022 Direct
holding REGN Common Stock 229 Mar 21, 2022 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -400 -2.08% $0.00 18.8K Mar 21, 2022 Common Stock 400 $381.92 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.